ABSTRACT
Anemia of chronic disease (ACD) is one of the most frequent forms of anemia is often observed in patients with infections, cancer and chronic inflammatory or autoimmune diseases. The underlying mechanisms are complex and include dysregulation of iron homeostasis and erythropoietin production, impaired proliferation of erythroid progenitor cells and reduced life span of red blood cells. Moreover, ACD is often superimposed by malnutrition, bleeding and renal failure. ACD is mediated through inflammatory cytokines and characterized by low serum iron (hypoferremia) and often increased reticuloendothelial stores of iron. ACD is usually normocytic, normochromic anemia, but it can become microcytic and hypochromic as the disease progresses. Hepcidin, the main regulator of iron homeostasis and its synthesis, is inhibited by iron deficiency and stimulated by inflammation. In many patients the disease is associated with several extrapulmonary manifestations regarded as the expression of the systemic inflammatory state of chronic obstructive pulmonary disease (COPD). Recent studies showed that anemia in patients with COPD is more frequent than expected, with its prevalence ranging from 8 to 33%. Systemic inflammation may be an important pathogenic factor, but anemia in COPD can also be the result of a number of factors, such as the treatment with certain drugs (angiotensin-converting enzyme inhibitors or theophylline), endocrine disorders, acute exacerbations and oxygen therapy. Anemia in COPD patients is strongly associated with increased functional dyspnea, decreased exercise capacity and is an independent predictor of mortality. Treatment options to correct anemia used in other chronic diseases, such as congestive heart failure, cancer or chronic kidney disease have not been explored in COPD (i.e. erythropoietic agents, iron supplements or combined therapy). It is not known whether treating the underlying inflammation could improve hematological characteristics. It is important to develop basic diagnostic modalities for this group of patients and formulate methods of anemia correction.
Subject(s)
Anemia , Iron/metabolism , Pulmonary Disease, Chronic Obstructive , Anemia/etiology , Anemia/immunology , Anemia/therapy , Erythropoiesis/physiology , Humans , Inflammation/blood , Patient Care Management/methods , Pulmonary Disease, Chronic Obstructive/blood , Pulmonary Disease, Chronic Obstructive/complicationsABSTRACT
The article concerns the efficacy of the use of new therapeutic approach in the therapy of secondary osteoarthritis in patients with rheumatoid arthritis. The dynamic of Cartilage Oligomeric Matrix Protein, activity of the disease on DAS28, cytokine profile was estimated. The analysis of the results showed the advantages of the use of inhibitor of IL-1 combined with laser therapy in the treatment of secondary osteoarthritis in patients with rheumatoid arthritis.
Subject(s)
Anthraquinones/therapeutic use , Arthritis, Rheumatoid/drug therapy , Cartilage Oligomeric Matrix Protein/blood , Interleukin-1/antagonists & inhibitors , Low-Level Light Therapy/methods , Osteoarthritis/drug therapy , Aged , Anthraquinones/administration & dosage , Arthritis, Rheumatoid/complications , Arthritis, Rheumatoid/immunology , Arthritis, Rheumatoid/radiotherapy , Combined Modality Therapy , Female , Humans , Male , Middle Aged , Osteoarthritis/etiology , Osteoarthritis/immunology , Osteoarthritis/radiotherapy , Treatment OutcomeABSTRACT
Activity of NADP-dependent isocitrate dehydrogenase (EC 1.1.1.42) increases and the catalytic characteristics of the enzyme isolated from the liver of rats are changed under conditions of apoptosis induction in comparison with these characteristics in health. Injection of melatonin induced a trend to normalization of kinetic parameters of catalytic activity and of some regulatory characteristics of the enzyme.
Subject(s)
Isocitrate Dehydrogenase/metabolism , Liver/enzymology , Melatonin/pharmacology , Tumor Necrosis Factor-alpha/pharmacology , Animals , Apoptosis/drug effects , Catalysis , Chromatography, Gel , Chromatography, Ion Exchange , Dactinomycin/administration & dosage , Dactinomycin/pharmacology , Electrophoresis , Injections, Intraperitoneal , Isocitrate Dehydrogenase/isolation & purification , Kinetics , Rats , SpectrophotometryABSTRACT
Development of apoptosis is accompanied by a decrease in transcripts of NADP-isocitrate dehydrogenase (NADP-IDH, E.C. 1.1.1.42.), and also alterations of catalytic properties from the rat liver enzyme in comparison with control. Administration of thioctic acid is increased the level of expression towards normal values. Enzyme preparations NADP-IDH were obtained from rat liver at norm conditions, after introduction of tumor necrosis factor and thioctic acid action under apoptosis. Molecular weight of homogenous preparations of NADP-IDH purified from livers of control and experimental rats was 112 +/- 5.8 kDa, however Km values and pH-optimum changed in apoptosis. Regulation of NADP-IDH activity under effect of some intermediates of the tricarboxylic acid cycle also differed in these groups.
